Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01407562 · ClinicalTrials.gov registry record · Phase 1
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01407562 is a Phase 1 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 34 participants.
The verdict
NCT01407562, a Phase 1 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is an open label, dose escalation study to determine the safety and tolerability and maximum tolerated dose of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid tumors.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-09-17 |
| Est. Completion | 2016-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01407562
The ClinicalTrials.gov registry entry for NCT01407562 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01407562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01407562 about?
NCT01407562 is a clinical study titled "Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors". This is an open label, dose escalation study to determine the safety and tolerability and maximum tolerated dose of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid tumors.
What is the current status of trial NCT01407562?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2010-09-17. Estimated completion is 2016-03-29.
What interventions are being tested in trial NCT01407562?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01407562?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.